2 results
Approved WMOPending
STUDY OBJECTIVESTo determine whether NAC therapy results in decreased red cell PS exposure, endothelial activation, inflammation, and reduction clotting activation in the steady state.
Approved WMORecruiting
This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of RO7284755 (alone or incombination with atezolizumab) and to evaluate its anti-tumor activity.